Loading...
Loading...
Apricus Biosciences, Inc.
("Apricus Bio" or the "Company")
APRI (http://www.apricusbio.com),
today announced that its marketing application for Vitaros^®, indicated for
the treatment of patients with erectile dysfunction ("ED"), has been approved
through the European Decentralized Procedure ("DCP").
Under the DCP, Apricus Bio filed its application for marketing approval
designating Netherlands as the Reference Member State ("RMS") on behalf of
nine other European Concerned Member States ("CMS") participating in the
procedure. The CMS include France, Germany, Italy, UK, Ireland, Spain, Sweden,
Belgium and Luxembourg. The Company will continue to work independently as
well as with its commercialization partners, Sandoz, Takeda, and Bracco for
the next step of obtaining national phase approvals in order to make Vitaros^®
ready to launch in each of the included territories across Europe.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in